P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Bibliographic Details
Main Authors: D.E. Lowther, E.A. Houseman, G. Han, E. Kleanthous, D. Knoblock, X. Zhou, S. Banerjee, S. Patel, D. Figueroa
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000936292.14792.3e

Internet

http://journals.lww.com/10.1097/01.HS9.0000936292.14792.3e

Similar Items